ACRV Valuation

Acrivon Therapeutics Inc

Add to Watchlist

Advanced Chart

2.330

+0.34(17.085%)1D

ACRV Relative Valuation

ACRV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACRV is overvalued; if below, it's undervalued.

Historical Valuation

Acrivon Therapeutics Inc (ACRV) is now in the Fair zone, suggesting that its current forward PS ratio of 1.99 is considered Fairly compared with the five-year average of -2.75. The fair price of Acrivon Therapeutics Inc (ACRV) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.21

Fair

-0.79

Trailing

Forward

0.00

EV/EBITDA

Acrivon Therapeutics Inc. (ACRV) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.74

EV/EBIT

Acrivon Therapeutics Inc. (ACRV) has a current EV/EBIT of 0.74. The 5-year average EV/EBIT is -1.04. The thresholds are as follows: Strongly Undervalued below -5.28, Undervalued between -5.28 and -3.16, Fairly Valued between 1.09 and -3.16, Overvalued between 1.09 and 3.21, and Strongly Overvalued above 3.21. The current Forward EV/EBIT of 0.74 falls within the Historic Trend Line -Fairly Valued range.

1.99

Acrivon Therapeutics Inc. (ACRV) has a current PS of 1.99. The 5-year average PS is 67.00. The thresholds are as follows: Strongly Undervalued below -244.59, Undervalued between -244.59 and -88.79, Fairly Valued between 222.79 and -88.79, Overvalued between 222.79 and 378.59, and Strongly Overvalued above 378.59. The current Forward PS of 1.99 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Acrivon Therapeutics Inc. (ACRV) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.84. The thresholds are as follows: Strongly Undervalued below -7.50, Undervalued between -7.50 and -5.17, Fairly Valued between -0.51 and -5.17, Overvalued between -0.51 and 1.82, and Strongly Overvalued above 1.82. The current Forward P/OCF of 0.00 falls within the Overvalued range.

-0.75

P/FCF

Acrivon Therapeutics Inc. (ACRV) has a current P/FCF of -0.75. The 5-year average P/FCF is -2.73. The thresholds are as follows: Strongly Undervalued below -6.25, Undervalued between -6.25 and -4.49, Fairly Valued between -0.97 and -4.49, Overvalued between -0.97 and 0.79, and Strongly Overvalued above 0.79. The current Forward P/FCF of -0.75 falls within the Overvalued range.

Acrivon Therapeutics Inc (ACRV) has a current Price-to-Book (P/B) ratio of 0.44. Compared to its 3-year average P/B ratio of 1.06 , the current P/B ratio is approximately -58.57% higher. Relative to its 5-year average P/B ratio of 1.06, the current P/B ratio is about -58.57% higher. Acrivon Therapeutics Inc (ACRV) has a Forward Free Cash Flow (FCF) yield of approximately -116.93%. Compared to its 3-year average FCF yield of -50.19%, the current FCF yield is approximately 133.00% lower. Relative to its 5-year average FCF yield of -50.19% , the current FCF yield is about 133.00% lower.

0.44

P/B

Median3y

1.06

Median5y

1.06

-116.93

FCF Yield

Median3y

-50.19

Median5y

-50.19

Competitors Valuation Multiple

The average P/S ratio for ACRV's competitors is 1.98, providing a benchmark for relative valuation. Acrivon Therapeutics Inc Corp (ACRV) exhibits a P/S ratio of 1.99, which is 0.59% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ACRV.O

Acrivon Therapeutics Inc

Werewolf Therapeutics Inc

Reviva Pharmaceuticals Holdings Inc

0.60

56.83M

Performance Decomposition

Market capitalization of ACRV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ACRV in the past 1 year is driven by Unknown.